Polycarboxylic fatty acid/selective estrogen receptor degrader - NovoLipidAlternative Names: Polycarboxylic fatty acid/SERD; Polycarboxylic fatty acid/SERD conjugate
Latest Information Update: 25 Jul 2016
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer NovoLipid
- Class Drug conjugates; Fatty acids
- Mechanism of Action Selective estrogen receptor degraders
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours